some nervousness about integration issues, etc. Of course,...

some nervousness about integration issues, etc. Of course, that's always an issue but there are some really re-assuring statements in today's announcement which seems to reduce these risks materially:

- PGC and REM "... are very similar in structure, strategy and delivery"
- "... The vendors and executive management team will be remaining with the business throughout the earn-out period".
- reasonable earn-out period and incentives: every $ of EBITDA growth they get paid $4.5
- "The REM business has recorded strong organic growth over recent years in the range of 6% pa – 8% pa". so good momentum, not requiring new mgmt/strategy/change in focus etc. no need for PGC to step in
- "... REM’s commanding presence in the New Zealand healthcare market and valuable product lines provides opportunity to leverage the Paragon portfolio. REM is simply a fantastic spearhead investment into the New Zealand market".

all very re-assuring indeed. GLAH